Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lantern PharmaLTRN -0.34%33 5-Year RORE % is 2.42 as of Mar. 2026. GuruFocus rates LTRN with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,136 Biotechnology companies, Lantern Pharma ranks better than 69.89% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Lantern Pharma's 5-Year RORE % for the quarter that ended in Mar. 2026 was 2.42%.
The industry rank for Lantern Pharma's 5-Year RORE % or its related term are showing as below:
LTRN's 5-Year RORE % is ranked better than 69.89% of 1136
companies
in the Biotechnology industry
Industry Median: -10.675
vs LTRN: 2.42
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Lantern Pharma 5-Year RORE % Related Terms
Lantern Pharma 5-Year RORE % Historical Data
* Premium members only.
The historical data trend for Lantern Pharma's 5-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lantern Pharma's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lantern Pharma 5-Year RORE % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lantern Pharma's 5-Year RORE % distribution charts can be found below:
* The bar in red indicates where Lantern Pharma's 5-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 5-year before.
Lantern Pharma (LTRN) has a 5-Year RORE % of 2.42 as of Mar. 2026. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Lantern Pharma and its competitors. According to the industry distribution chart, Lantern Pharma ranks #342 out of 1136 companies in the Biotechnology industry, placing it in the top 30.1%.
Is Lantern Pharma's 5-Year RORE % too high?
Lantern Pharma's current 5-Year RORE % is 2.42. Based on the distribution chart, Lantern Pharma ranks #342 out of 1136 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lantern Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Lantern Pharma's 5-Year RORE % compare to PDSB and AURX?
According to the Biotechnology industry distribution chart, Lantern Pharma ranks #342 out of 1136 companies for 5-Year RORE %. This puts Lantern Pharma in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year RORE % for a Biotechnology company?
A good 5-Year RORE % depends on the Biotechnology industry context. However, 5-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year RORE % mean?
A high 5-Year RORE % can signal that a stock is expensive relative to its fundamentals. 5-Year RORE % shows how much a company earns by reinvesting its retained earnings in 5-year. View historical data on Lantern Pharma and its competitors. Lantern Pharma's current 5-Year RORE % is 2.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lantern Pharma stock overvalued right now?
Lantern Pharma (LTRN) has a current 5-Year RORE % of 2.42. The current 5-Year RORE % is 2.42. Lantern Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year RORE % calculated?
5-Year RORE % is calculated from a company's financial statements. For Lantern Pharma (LTRN), the current 5-Year RORE % is 2.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
33GF Score
Get the complete analysis for LTRN
5-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTRN has been successfully added to your 
